Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas Medicine(EDIT) Zacks Investment Research·2024-02-28 22:11
Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of $0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%.Over the last four quarters, the compa ...